替莫唑胺剂量密集方案联合安罗替尼治疗复发高级别脑胶质瘤

Anlotinib in combination with temozolomide dose-dense regimen in patients with recurrent high-grade glioma

目的评估替莫唑胺剂量密集方案与安罗替尼联合治疗在复发高级别脑胶质瘤患者中的疗效和安全性。方法选取2018年1月至2023年2月在宁波大学附属第一医院接受替莫唑胺剂量密集方案与安罗替尼联合治疗的42例复发高级别脑胶质瘤患者的临床数据,评估其近期疗效、生存情况和不良反应。结果42例复发高级别脑胶质瘤患者中,世界卫生组织(World Health Organization,WHO)4级26例,WHO 3级16例。客观缓解率为38.1%,疾病控制率为81.0%。中位无进展生存期(progression free survival,PFS)为5.2个月,中位总生存期(overall survival,OS)为8.6个月,6个月PFS率为38.1%,12个月OS率为14.3%。主要不良反应包括手足皮肤反应、高血压、骨髓抑制和胃肠道反应,均为1~2级。结论替莫唑胺剂量密集方案联合安罗替尼治疗复发高级别脑胶质瘤患者表现出明显的疗效,且不良反应可耐受。

Objective To analyze the efficacy and safety of combining anlotinib with temozolomide dose-dense regimen for recurrent high-grade glioma.Methods The clinical data of 42 patients who had recurrent high-grade glioma and were treated with the combined therapy of anlotinib and temozolomide dose-dense regimen at the First Affiliated Hospital of Ningbo University from January 2018 to February 2023 were collected.The short-term effect,survival,and adverse events were assessed.Results Among the 42 patients with recurrent high-grade glioma,26 cases were World Health Organization(WHO)grade 4,and 16 cases were WHO grade 3.The objective response rate was 38.1%,and the disease control rate reached 81.0%.The median progression free survival(PFS)was 5.2 months,and the 6-month PFS rate was 38.1%.The median overall survival(OS)was 8.6 months,and the 12-month OS rate was 14.3%.Among the most frequently reported treatment-related adverse events were hand-foot skin reaction,hypertension,marrow suppression,and gastrointestinal reactions.All treatment-related adverse events were grade 1 or 2.Conclusions Combining anlotinib with temozolomide dose-dense regimen has promising efficacy and well-tolerated adverse events in patients with recurrent high-grade glioma.